Direct-acting oral anticoagulants include dabigatran, which is a thrombin inhibitor, and rivaroxaban, apixaban, and edoxaban, which are anti-Xa agents. These are administered in the secondary prophylaxis and treatment of venous thromboembolism (VTE) and pulmonary embolism (PE), in the prophylaxis of VTE that may develop after major elective orthopedic surgery, in reducing stroke and systemic embolism that may occur in non-valvular atrial fibrillation, whereas its use in acute coronary syndrome is still controversial. Although it is specified that direct-acting oral anticoagulants are as effective as heparin therapy and reduce the risk of bleeding due to all causes, many important studies have also reported that they increase the risk of gastrointestinal system (GIS) bleeding.
Gastrointestinal Bleeding Direct Acting Oral Anticoagulants Endoscopy
Yok
Yok
Yok
Doç Dr Talat Ayyıldız'a nazik daveti için teşekkür ederiz
Birincil Dil | İngilizce |
---|---|
Konular | Sağlık Kurumları Yönetimi |
Bölüm | Clinical Research |
Yazarlar | |
Proje Numarası | Yok |
Yayımlanma Tarihi | 18 Mart 2021 |
Gönderilme Tarihi | 10 Eylül 2020 |
Kabul Tarihi | 18 Kasım 2020 |
Yayımlandığı Sayı | Yıl 2021 Cilt: 38 Sayı: 2s |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.